Public Employees Retirement System of Ohio Lowers Stock Holdings in Charles River Laboratories Intl. Inc (NYSE:CRL)

Public Employees Retirement System of Ohio trimmed its position in shares of Charles River Laboratories Intl. Inc (NYSE:CRL) by 5.3% in the second quarter, HoldingsChannel.com reports. The fund owned 34,765 shares of the medical research company’s stock after selling 1,964 shares during the period. Public Employees Retirement System of Ohio’s holdings in Charles River Laboratories Intl. were worth $4,933,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Flagship Harbor Advisors LLC boosted its holdings in Charles River Laboratories Intl. by 132.1% during the 2nd quarter. Flagship Harbor Advisors LLC now owns 318 shares of the medical research company’s stock valued at $45,000 after acquiring an additional 181 shares during the period. Steward Partners Investment Advisory LLC purchased a new position in Charles River Laboratories Intl. during the 2nd quarter valued at about $69,000. Machina Capital S.A.S. purchased a new position in shares of Charles River Laboratories Intl. in the 2nd quarter valued at about $72,000. Hilton Capital Management LLC purchased a new position in shares of Charles River Laboratories Intl. in the 1st quarter valued at about $118,000. Finally, Cigna Investments Inc. New purchased a new position in shares of Charles River Laboratories Intl. in the 1st quarter valued at about $201,000. Institutional investors own 94.40% of the company’s stock.

Several equities analysts have recently issued reports on the company. Zacks Investment Research cut Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research note on Monday. ValuEngine cut Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Leerink Swann assumed coverage on Charles River Laboratories Intl. in a research note on Monday, June 10th. They issued an “outperform” rating for the company. Finally, Svb Leerink assumed coverage on Charles River Laboratories Intl. in a research note on Monday, June 10th. They issued an “outperform” rating and a $155.00 price objective for the company. Seven research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Charles River Laboratories Intl. currently has an average rating of “Buy” and a consensus price target of $147.62.

In other Charles River Laboratories Intl. news, insider David Ross Smith sold 1,249 shares of Charles River Laboratories Intl. stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $130.36, for a total transaction of $162,819.64. Following the transaction, the insider now owns 19,327 shares of the company’s stock, valued at $2,519,467.72. The transaction was disclosed in a filing with the SEC, which is available at this link. 1.80% of the stock is currently owned by company insiders.

Shares of NYSE CRL traded up $0.47 during midday trading on Friday, hitting $132.27. 108,926 shares of the company’s stock were exchanged, compared to its average volume of 246,825. The company has a debt-to-equity ratio of 1.47, a current ratio of 1.59 and a quick ratio of 1.38. Charles River Laboratories Intl. Inc has a twelve month low of $103.00 and a twelve month high of $149.07. The company has a market cap of $6.33 billion, a PE ratio of 21.93, a P/E/G ratio of 1.66 and a beta of 1.09. The firm’s fifty day simple moving average is $131.96 and its 200-day simple moving average is $136.28.

Charles River Laboratories Intl. (NYSE:CRL) last issued its earnings results on Wednesday, July 31st. The medical research company reported $1.63 earnings per share for the quarter, topping the consensus estimate of $1.55 by $0.08. Charles River Laboratories Intl. had a return on equity of 22.01% and a net margin of 8.94%. The business had revenue of $657.60 million for the quarter, compared to analyst estimates of $662.61 million. During the same quarter last year, the company earned $1.62 EPS. The business’s quarterly revenue was up 12.4% on a year-over-year basis. Equities analysts anticipate that Charles River Laboratories Intl. Inc will post 6.52 EPS for the current fiscal year.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

See Also: Why are trading ranges significant?

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories Intl. Inc (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.